Association between metabotropic glutamate receptor 3 gene (GRM3) polymorphisms and the clinical and neuroanatomical characteristics in patients with schizophrenia
Abstract
The metabotropic glutamate 3 receptor gene (GRM3) polymorphisms were reported to be associated with schizophrenia, and with schizophrenia-related endophenotypes such as impaired cognition, cortical activation and glutamate markers, but the existing findings have remained inconsistent. To evaluate the association between GRM3 polymorphisms and the clinical and neuroimaging profiles in patients with schizophrenia, we conducted cross-sectional study with ninety-four subjects.
We selected three SNP (rs1468412, rs2228595, rs6465084), previously reported to be associated with schizophrenia, and with prefrontal brain functioning. Subjects completed ratings of the PANSS and neurocognitive testing and subset of patients underwent 18-fluorodeoxyglucose positron emission tomography (18-FDG PET; n = 84) and 1.5 T structural magnetic resonance imaging (MRI; n = 56) followed by automated voxel-based morphometry (VBM).
No significant evidences for association between tested GRM3 polymorfisms genotypes and haplotypes and clinical characteristics, neurocognitive functioning, specific metabolic patterns as well as regional brain volumes differences were found. Our study of GRM3 gene polymorphisms did not provide support for genetic association with clinical and neuroimaging profiles in patients with schizophrenia